The History of Asthma Drugs from Astra Pharmaceuticals and AstraZeneca R&D

References

1.	Sims J. Datura stramonium or thorn apple as a cure or relief for asthma. Edinburgh Medical and Surgical Journal 1812; 8: 364-367
2.	Salter HH . On Asthma: Its pathology and treatment. J Churchill 1860; 177-204
3.	Salter HH. On the treatment of asthma by belladonna. Lancet 1869; i: 152-153
4.	Oliver G, Schäfer EA. On the physiological action of extract of the suprarenal capsules. J Physiol (Lond) 1895; 17: 9-14
5.	Solis-Cohen S. The use of adrenal substance in the treatment of asthma. JAMA 1900; 34: 1164-1166
6.	Bulowa JGM, Kaplan DM. On the hypodermic use of adrenalin chloride in the treatment of asthmatic attacks. Med News 1903; 83: 787-790
7.	Chen KK, Schmidt CF. The action of ephedrine, the active principle of the Chinese drug Ma Huang. J Pharm Exp Ther 1924; 24: 339-357
8.	Herrmann G, Aynesworth MB, Martin J. Successful treatment of persistent extreme dyspnea, "Status asthmaticus" - use of theophylline ethylene diamine (aminophylline, U.S.P.) intravenously. J Lab Clin Med 1937; 23: 135-148
9.	Greene JA, Paul WD, Feller AE. The action of theophylline with ethylenediamine on intrathecal and venous presures in cardiac failure and on bronchial obstruction in cardiac failure and in bronchial asthma. JAMA 1937; 109: 1712-1714
10.	Konzett H, Neue broncholytische hochwirksame Körper der Adrenalinreihe. Naunyn-Schmiedeberg Arch Exp Pathol Pharmacol 1941; 197: 2734.
11.	Hartley D, Jack D, Lunts LHC, Ritchie AC. New class of selective stimulants of ß-adreneric receptors. Nature 1968; 219: 118
12.	Choo-Kang YFJ, Simpson WT, Grant IWB. Controlled comparison of the bronchodilator effects of three ß-adreneric stimulant drugs administered by inhalation to patients with asthma. BMJ 1969; 2: 287-289
13.	Persson H, Olsson T. Some pharmacological properties of terbutaline (NN),1-(3,5-dihydroxyphenyl)-2(t-butylamino)-ethanol. A new sympathomimetic ß-receptor-stimulating agent. Acta med scand 1970; 512 (suppl): 11-19
14.	Vathenen AS, Knox AJ, Higgins BG, Britton JR, Tattersfield AE. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet 1988; 1: 554-558
15.	Cockcroft DW, McParland CP, Britto SA, Swystun VA, Rutherford BC. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 1993; 342: 833-837
16.	Sears MR, Taylor DR, Print CG, Lake DC, Li Q, Flannery EM, Yates DM, Lucas MK, Herbison GP. Regular inhaled -agonist treatment in bronchial asthma. Lancet 1990; 336: 1391-1396
17.	Morrow Brown H, Storey G, George WHS. Beclomethasone dipropiopnate: a new steroid aerosol for the treatment of asthma. BMJ 1972; 1: 585-590
18.	Thalén A, Brattsand R. Synthesis and anti-inflammatory properties of budesonide, a new non-halogenated glycocorticoid with high local activity. Arzneim-Forsch/Drug Res 1979; 29: 1687-1690
19.	Brattsand R, Thalén A, Roempke K, Källström L, Gruvstad E. Development of a new glucocorticosteroid with a very high ratio between topical and systemic activities. Eur J Respir Dis 1982; 63, suppl 122: 62-73
20.	Ellul-Micallef R, Johansson S-Å. Acute dose-response studies in bronchial asthma with a new corticosteroid, budesonide. Br J Clin Pharmacol 1983; 15: 419-422
21.	Dahl R, Johansson S-Å. Importance of duration of treatment with inhaled budesonide on the immediate and late bronchial reaction. Eur J Respir Dis 1982; 63, suppl 122: 167-175
22.	Kraan J, Koeter GH, van der Mark TH, Sluiter HJ, deVries K. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J Allergy Clin Immunol 1985; 76: 628-636
23.	Kraan J, Koeter GH, van der Mark TH, Boorsma M, Kukler J, Sluiter HJ, deVries K. Dosage and time effects of inhaled budesonide on bronchial hyperreactivity. Am Rev Respir Dis 1988; 137: 44-48
24.	Bel EH, Timmers MC, Zwinderman AH, Dijkman JH, Sterk PJ. The effect of inhaled corticosteroids on the maximal degree of airway narrowing to methacholine in asthmatic subjects. Am Rev Respir Dis 1991; 143: 109-113
25.	Haahtela T, Järvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Reinikainen K, Selroos O, Sovijärvi A, Stenius-Aarniala B, Svahn T, Tammivaara R, Laitinen LA.. Comparison of a 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325: 388-392
26.	Laitinen LA, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized double-blind, parallel-group controlled trial. J Allergy Clin Immunol 1992;90:32-42
27.	Haahtela T, Järvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Selroos O, Sovijärvi A, Stenius-Aarniala B, Svahn T, Tammivaara R, Laitinen LA.. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994; 331: 700-705
28.	Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994; 88: 373-381
29.	Selroos O, Pietinalho A, Löfroos A-B, Riska H. Effect of early vs late intervention with inhaled corticosteroids in asthma. Chest 1995; 108: 1228-1234
30.	Osterman K, Carlholm M, Ekelund J, Kiviloog J, Nikander K, Nilholm L, Salomonsson P, Strand V, Venge P, Zetterström O. Effect of 1 year daily treatment with 400 g budesonide (Pulmicort Turbuhaler) in newly diagnosed asthmatics. Eur Respir J 1997; 10: 2210-2215
31.	Selroos O, Löfroos A-B, Pietinalho A, Riska H. Asthma control and steroid doses 5 years after early or delayed introduction of inhaled corticosteroids in asthma: a real life study. Respir Med 2004; 98: 254-262
32.	Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV, Ullman A, Lamm CJ, O´Byrne PM and START investigators group. Early intervention in mild persistent asthma: a randomized double-blind study. Lancet 2003; 361: 1071-1076.
33.	Miyamoto T, Takahashi T, Nakajima S, Makino S, Yamakido M, Mano K, Nakashima M, Tollemar U, Selroos O. A double-blind, placebo-controlled dose-response study with budesonide Turbuhaler in Japanese asthma patients. Respirology 2000; 5: 259-268
34.	Busse WW, Chervinsky P, Condemi J, Lumry WR, Petty TL, Rennard S, Townley RG. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adults with chronic asthma. J Allergy Clin Immunol 1998; 101: 457-463
35.	Shapiro G, Bronsky EA, LaForce CF, Mendelson L, Pearlman D, Schwartz RH, Szefler SJ. Dose-related efficacy of budesonide administered via a dry powder inhaler in the treatment of children with moderate to severe persistent asthma. J Pediatr 1998; 132: 976-982
36.	Selroos O, Edsbäcker S, Hultquist C. Once-daily inhaled budesonide for the treatment of asthma: clinical evidence and pharmacokinetic explanation. J Asthma 2004; 41: 771-790
37.	Edsbäcker S, Brattsand R. Budesonide fatty-acid esterification: a novel mechanism prolonging binding to airway tossue. Review of available data. Ann Allergy Asthma Immunol 2002; 88: 609-616
38.	Szefler SJ. A review of budesonide inhalation suspension in the treatment of pediatric asthma. Pharmacotherapy 2001; 21: 195-206
39.	Szefler SJ, Eigen H. Budesonide inhalation suspension: a nebulized corticosteroid for persistent asthma. J Allergy Clin Immunol 2002; 109: 730-742
40.	Miyamoto T, Takahashi T, Nakajima S, Makino S, Yamakido M, Mano K, Nakashima M, Tollemar U, Selroos O. Efficacy of budesonide Turbuhaler compared with that of beclomethasone dipropionate pMDI in Japanese patients with moderately severe asthma. Respirology 2001; 6: 27-35
41.	Agertoft L, Pedersen S. A randomized double-blind dose reduction study to compare the minimal effective dose of budesonide Turbuhaler and fluticasone propionate Diskhaler. J Allergy Clin Immunol 1997; 99: 773-780
42.	Kuna P, Joubert JR, Greefhorst LAPM, Magnusson H. A randomized, double-blind, double-dummy, parallel-group, multicenter, dose-reduction trial of the minimal effective doses of budesonide and fluticasone dry-powder inhalers in adults with mild to moderate asthma. Clin Ther 2003; 25: 2182-2197
43.	Thorsson L, Edsbäcker S, Conradson TB. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered dose inhaler (pMDI). Eur Respir J 1994; 7: 1839-1844
44.	Löfdahl C-G, Svedmyr N. Effect duration of inhaled formoterol, a new 2-adrenoceptor agonist, compared with salbutamol in asthmatic patients. Acta pharmacol toxicol 1986; 5, suppl: 229
45.	Ullman A, Svedmyr N. Salmeterol, a new long acting inhaled 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax 1988; 43: 674-678
46.	Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing ICS. Lancet 1994; 344: 219-224
47.	Woolcock A, Lundbäck B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153: 1481-1488
48.	Pauwels RA, Löfdahl C-G, Postma DS, Tattersfield AE, O´Byrne P, Barnes PJ, Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. New Engl J Med 1997; 337: 1405-1411
49.	Kips JC, O´Connor BJ, Inman MD, Svensson K, Pauwels RA, O´Byrne PM. A long-term study of antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med 2000; 161: 996-1001
50.	O´Byrne PM, Barnes PJ, Rodriques-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, Tattersfield A. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164: 1392-1397
51.	Rosenborg J, Larsson P, Rott Z, Böcskei C, Poczi M, Juhász G. Relative therapeutic index between inhaled formoterol and salbutamol in asthma patients. Respir Med 2002; 96 :412-417
52.	Tötterman KJ, Huhti L, Sutinen E, Backman R, Pietinalho A, Falck M, Larsson P, Selroos O. Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients. Eur Respir J 1998; 12: 573-579
53.	Malolepszy J, Böszörményi Nagy G, Selroos O, Larsson P, Brander R. Safety of formoterol Turbuhaler at cumulative dose of 90 g in patients with acute bronchial obstruction. Eur Respir J 2001; 18: 928-934
54.	Boonsawat W, Charoenratanakul S, Pothirat C, Sawanyawisuth K, Seearamroongruang T, Bengtsson T, Brander R, Selroos O. Formoterol (Oxis ) Turbuhaler as resue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma. Respir Med 2003; 97: 1967-1074
55.	Tattersfield AE, Löfdahl C-G, Postma DS, Eivindson A, Schreurs AGM, Rasidakis A, Ekström T. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet 2001; 357: 257-261
56.	Pauwels RA, Sears MR, Campbell M, Villasante C, Huang S, Lindh A, Petermann W, Aubier M, Schwabe G, Bengtsson T. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J 2003; 22:787-94
57.	Zetterström O, Buhl R, Mellem H, Perpiña, Hedman J, O´Neill S, Ekström T. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 2001; 18: 262-26
58.	FitzGerald JM, Becker A, Sears MR, Mink S, Chung K, Lee J and the Canadian Asthma Exacerbation Study Group. Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax 2004; 59: 550-556
59.	Harrison TW, Oborne J, Newton S, Tattersfield AE. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 2004; 363: 271-275
60.	Foresi A, Morelli MC, Catena E. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. Chest 2000;117: 440-446
61.	Ställberg B, Olsson P, Jörgensen LA, Lindarck N, Ekström T. Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. Int J Clin Pract 2003; 57: 656-661
62.	Fitzgerald JM, Sears MR, Boulet L-P, Becker AB, McIvor AR, Ernst PE, Smiljanic-Georgijev NM, Lee JSM. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study. Can Respir J 2003; 10: 427-434
63.	Aalbers R, Backer V, Kava TTK, Omenaas ER, Sandström T, Jorup C, Welte T. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin 2004; 20: 225-240
64.	Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic opatients: onset of action, duration of effect and potency. Eur Respir J 1997; 10: 2484-2489
65.	Palmqvist M, Arvidsson P, Beckman O, Peterson S, Lötvall J. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers. Pulm Pharmacol Ther 2001; 14: 29-34
66.	Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med 2000; 161: 64-72.
67.	Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006; 368: 744-753..